Monitor whether T. Rowe Price files a 13D (activist conversion) or continues to adjust its position in future 13G amendments. The passive nature of this filing suggests no imminent activist intent.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $63.89entry
- T+1 · 8d ago +5.70%α +3.33% · $67.53
- T+5 · 4d ago −0.81%α −3.41% · $63.37
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing a 9.6% passive stake in Vaxcyte as of September 30, 2026, up from a prior filing. The increase in a passive holding is neutral; the filing follows positive Phase 3 data for VAX-31 and a $1.1B capital raise reported two days earlier.
Key Financial Metrics
Key Facts
- T. Rowe Price Investment Management reported beneficial ownership of 14,312,368 shares of Vaxcyte common stock as of September 30, 2026.
- The stake represents 9.6% of shares outstanding.
- This is an amendment (SC 13G/A) updating a prior passive stake filing.
- The filing certifies the securities were acquired and held in the ordinary course of business, not to influence control.
Financial Impact
T. Rowe Price holds 14,312,368 shares, 9.6% of Vaxcyte, valued at approximately $986M based on the $10.3B market cap snapshot.
Risk Factors
- A future conversion to Schedule 13D could signal activist intent, though not indicated here.
- A reduction below 5% in a future filing could be viewed as loss of institutional confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001897612-26-000700 |
| Document: 0001897612-26-000700-index.html | 0001897612-26-000700 |
| Document: 0001897612-26-000700.txt | 0001897612-26-000700 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $61.61 −1.27% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $61.61 −4.76% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Viewing Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers